Huons Nizatidine Capsule 150mg

Adult dose

1. Treatment of active gastric and duodenal ulcers Adults: Administer nizatidine 300mg once daily at bedtime, or 150mg twice daily, in the morning and evening, orally. Most ulcers heal within 4 weeks, but treatment may be continued for up to 8 weeks if needed. In cases of active gastric ulcer, malignancy must be ruled out before treatment. 2. Prevention of recurrence of duodenal ulcers After healing of a duodenal ulcer, adults should take 150mg orally once daily at bedtime. Treatment may be continued for up to 1 year; outcomes with longer-term administration are not known. 3. Gastroesophageal reflux disease Adults: Administer 150mg orally twice daily, in the morning and evening. Treatment may be continued for up to 12 weeks. 4. Improvement of gastric mucosal lesions Adults: Administer 150mg orally twice daily, in the morning and evening, for 2 weeks. 5. Dosage adjustment in patients with severe renal impairment Reduce the dose for patients with renal impairment as follows. Active duodenal ulcer, gastroesophageal reflux disease (GERD), benign gastric ulcer: Creatinine clearance 20~50 ml/min, 150mg daily Active duodenal ulcer, gastroesophageal reflux disease (GERD), benign gastric ulcer: Creatinine clearance < 20 ml/min, 150mg every other day Maintenance therapy: Creatinine clearance 20~50 ml/min, 150mg every other day Maintenance therapy: Creatinine clearance < 20 ml/min, 150mg every 3 days Some elderly patients may have creatinine clearance below 50mL/min. Based on pharmacokinetic data in patients with renal impairment, the dose should also be reduced in such patients according to the degree of renal impairment. The clinical effects of this dose reduction in patients with renal impairment have not been evaluated.

This medication should not be administered to certain patients. In particular, it should not be used in patients with allergies to this medication or other H2-receptor antagonists. Also, because it contains lactose, patients with lactose intolerance or related genetic diseases should not receive it. Caution should be exercised in patients with a history of drug hypersensitivity or impaired liver or kidney function. In cases of reduced kidney function, drug concentrations may increase, necessitating a reduction in dosage or elongation of dosing intervals. Patients allergic to the yellow 5 colorant included in this medication should also be administered with care. When using this medication, rare instances of hypersensitivity reactions such as skin rash, itching, and difficulty breathing may occur, and use should be discontinued immediately if such symptoms arise. Hematological abnormalities such as anemia and thrombocytopenia have been reported; thus, administration should be halted if abnormal symptoms occur. Gastrointestinal side effects may include constipation, diarrhea, dry mouth, and nausea. Elevation of liver function test values or liver damage symptoms such as hepatitis and jaundice may occur rarely, so caution is advised. Central nervous system effects may include rarely headaches, drowsiness, dizziness, and confusion, with rare reports of seizures. Cardiovascular effects may include transient ventricular tachycardia. In women, rare occurrences of gynecomastia, erectile dysfunction, and decreased libido have been reported, although they are comparable to normal levels. Skin reactions may include sweating, urticaria, rashes, and dermatitis. This medication is primarily excreted through the kidneys; thus, patients with weak kidney function or the elderly should particularly undergo kidney function tests and adjust dosage accordingly. Pregnant or breastfeeding women should only use this medication if absolutely necessary, as its safety has not been fully established. Nursing mothers should be cautious as the drug may be secreted in breast milk. Safety in children has not been adequately verified, so caution is required in its use. This medication may mask symptoms of gastric cancer; therefore, it should be administered only after confirming that it is not a malignant condition, and if no therapeutic effect is observed, it is advisable to change to another treatment. In cases of overdose, symptoms such as vomiting, diarrhea, and excessive salivation may occur, and gastric lavage or supportive therapy should be performed as necessary. Hemodialysis is not effective in removing this medication. Lastly, this medication generally has few drug interactions; however, caution should be exercised when used concomitantly with high doses of aspirin, as blood salicylate levels may increase.

• Rash
• itching
• bronchial asthma
• laryngeal edema
• anaphylaxis symptoms
• anemia
• leukopenia
• neutrophilia
• thrombocytopenic purpura
• constipation

This medication may be sensitive to air and moisture, so it must be stored in a sealed container. It is recommended to maintain storage temperatures between 1 and 30 degrees Celsius to preserve the drug's efficacy and safety.

Appearance

A hard capsule with a yellow upper part and a light yellow lower part containing white to pale gray powder.

Package unit

30 capsules/bottle, 300 capsules/bottle